Dergiler / Retina-Vitreus / 2022 / Cilt: 31 - Sayı: 3

The Importance of Comorbidity with Low Culture Positivity in Patients with Endophthalmitis

Sayfa
235–242
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This study showed that patients with systemic comorbidities (inflammatory or non-inflammatory) in addition to DM and/or HT experienced longer hospitalization times and needed more IVI.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: This paper aims to assess the clinical outcomes in patients with endophthalmitis.
📊
Temel Bulgular & Veri:Methods: This retrospective study includes 40 eyes from 40 patients.
💡
Sonuç & Katkı:This study showed that patients with systemic comorbidities (inflammatory or non-inflammatory) in addition to DM and/or HT experienced longer hospitalization times and needed more IVI.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Purpose: This paper aims to assess the clinical outcomes in patients with endophthalmitis. The effect of comorbidities on hospitalization time, treatment management, and vision gain are also examined. Methods: This retrospective study includes 40 eyes from 40 patients. Endophthalmitis was divided into two groups, exogenous and endogenous. Culture results, comorbidities, hospitalization times, treatment management, and vision gain were examined. Patients with diabetes mellitus(DM) and/or hypertension(HT) were put in Comorbidity Group 1(CG1). Patients with systemic comorbidities (inflammatory or non-inflammatory comorbidities) in addition to DM and/or HT were put in Comorbidity Group 2(CG2). Results: Endophthalmitis was of exogenous origin in 25 eyes and endogenous origin in 15 eyes. The outcomes of exogenous and endogenous groups according to various parameters are as follows: Rates of culture positivity (16.0%/20.0%), pars plana vitrectomy(PPV) (56.0%/86.7%), intravitreal injection(IVI) (44.0%/13.3%), rePPV(4.0%/20.0%), two IVIs (52.0%/6.7%), more than two IVIs (20.0%/66.7%). In the exogenous group, the mean hospitalization time in CG1 and CG2 was 7.3 ± 2.5 and 10.5 ± 2.8 days, respectively. The mean number of IVIs in CG2 was 28% more than CG1. In the endogenous group, mean hospitalization time in CG1 and CG2 was 14.3 ± 10.1 and 22.0 ± 6.7 days, respectively. The mean number of IVIs in CG2 was 86% more than CG1. Conclusions: The culture and antibiogram findings were low; therefore, we increased surgical procedures and repeated IVI. This study showed that patients with systemic comorbidities (inflammatory or non-inflammatory) in addition to DM and/or HT experienced longer hospitalization times and needed more IVI.

🔖

Bu Makaleye Atıf Yap

FİLİK, A., GÜNGEL, H., ÖĞREDEN, T. (2022). The Importance of Comorbidity with Low Culture Positivity in Patients with Endophthalmitis. Retina-Vitreus, Cilt: 31 - Sayı: 3, 235–242. https://ajindex.com/articles/589010

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Safneck JR. Endophthalmitis: A review of recent trends. Saudi J Ophthalmol. 2012 Apr; 26: 181–9
  2. Connell PP, O’Neill EC, Fabinyi D et al. Endogenous endophthalmitis: 10-year experience at a tertiary referral centre. Eye (Lond). 2011;25:66-72
  3. Okada AA, Johnson RP, Liles WC et al. Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study. Ophthalmology 1994 May;101:832-8
  4. Krause L, Bechrakis N, Heimann H et al. Incidence and outcome of endophthalmitis over a 13-year period. Can J Ophthalmol. 2009 44:88–94
  5. Duric V, Clayton S, Leong ML, Li-Lian Yuan LL. Comorbidity Factors and Brain Mechanisms Linking Chronic Stress and Systemic Illness. Neural Plasticity 2016:1-16
  6. Kawashima M. Systemic Health and Dry Eye. Invest Ophthalmol Vis Sci. 2018 Nov 1;59: DES138-DES142
  7. Fang H, Liu Q, Xi M et al. Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19. J Investig Med. 2021;69:75-85
  8. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina 2010;30:1046-50
  9. Storey PP, Tauqeer Z, Yonekawa Y et al. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab. Am J Ophthalmol. 2019; 199:200-8
  10. Kuhn F, Gini G. Complete and Early Vitrectomy for Endophthalmitis (CEVE) as Today’s Alternative to the Endophthalmitis Vitrectomy Study. Vitreo-Retinal Surgery. 2007 Springer, 53-68
  11. Forster RK, Abbott RL, Gelender H. Management of infectious endophthalmitis. Ophthalmology 1980 87: 313–8
  12. Han DP, Wisniewski SR, Wilson LA et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study; the Endophthalmitis Vitrectomy Study Group. Am J Ophthalmol. 1996 122:1–17 13. Sandvig KU, Dannevig L. Postoperative endophthalmitis: establishment and results of a national registry. Journal of Cataract & Refractive Surgery 2013 29, 1273–80
  13. Barry P, Cordové L, Gardner S. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions. 2013 15. Dar N, Pillar S, Friehmann A et al. Endophthalmitis After Intravitreal Injections Versus Cataract Surgery: a 15-year cohort. Int ophthalmol. 2020;40:73-9
  14. Soliman MK, Gini G, Kuhn F et al. European Vitreo-Retinal Society (EVRS) Endophthalmitis Study Group. International Practice Patterns for the Management of Acute Postsurgical and Postintravitreal Injection Endophthalmi